ERBB2 and breast cancer: An analysis of neoadjuvant clinical trials (14) involving the randomized clinical trials of GeparQuinto (n=2491) (15, 16) and GeparSepto (n=1206) (17) from the German Breast Group (GBG) and Arbeitsgemeinschaft Gynäkologische Onkologie, Breast Group (AGO-B), found no statistically significant difference in the pathological complete response (pCR) rate between patients with HR-low/HER2-negative BC and those with TNBC (OR=1.47, 95% CI=0.89 to 2.42, P = 0.132).